Atossa Therapeutics (ATOS) said Tuesday that results from the ongoing phase 2 Evangeline trial showed that (Z)-endoxifen achieved target tissue concentrations and demonstrated substantial tumor suppression in premenopausal women with a type of breast cancer.
The drug candidate was generally well tolerated with manageable side effects, according to the company.
Based on findings from the pharmacokinetic run-in phase, the company plans to proceed with an amended protocol comparing (Z)-endoxifen 40 milligrams per day with ovarian function suppression to exemestane plus OFS.
Recruitment for this cohort will start in 2025, the company added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。